R&D | October 28, 2025
MilliporeSigma partners with Promega to advance 3-D cell drug discovery technologies
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
The product is indicated for the chronic management of patients with Urea Cycle Disorders
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
